Experienced in Peripheral T-Cell Lymphoma

Dr. Srinivas S. Devarakonda

Hematology | Hematology Oncology
Osu Internal Medicine LLC
460 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
16 Years of Experience
Experienced in Peripheral T-Cell Lymphoma
Osu Internal Medicine LLC
460 W 10th Ave, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Srinivas Devarakonda is a Hematologist and a Hematologist Oncology provider in Columbus, Ohio. Dr. Devarakonda has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Multiple Myeloma, Sickle Cell Disease, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Devarakonda is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Peripheral T-Cell Lymphoma.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
460 W 10th Ave, Columbus, OH 43210
Other Locations
OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: Ixazomib Citrate, Pevonedistat
Study Phase: Phase 1
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Drug
Study Drugs: Carfilzomib, Dexamethasone, Telaglenastat
Study Phase: Phase 1
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study
Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study
Enrollment Status: Terminated
Publish Date: September 28, 2023
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Daratumumab, Fludarabine, Melphalan, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 2
View 10 Less Clinical Trials

45 Total Publications

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 09, 2025
Similar Doctors
Elite in Peripheral T-Cell Lymphoma
Dr. Jonathan E. Brammer
Hematology
Elite in Peripheral T-Cell Lymphoma
Dr. Jonathan E. Brammer
Hematology

Osu Internal Medicine LLC

410 W 10th Ave, Doan 110, 
Columbus, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Brammer is a Hematologist in Columbus, Ohio. Dr. Brammer is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Brammer is currently accepting new patients.

Advanced in Peripheral T-Cell Lymphoma
Dr. John C. Reneau
Hematology
Advanced in Peripheral T-Cell Lymphoma
Dr. John C. Reneau
Hematology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Reneau is a Hematologist in Columbus, Ohio. Dr. Reneau is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reneau is currently accepting new patients.

Advanced in Peripheral T-Cell Lymphoma
Dr. Basem M. William
Hematology Oncology | Hospital Medicine | Transplant Surgery
Advanced in Peripheral T-Cell Lymphoma
Dr. Basem M. William
Hematology Oncology | Hospital Medicine | Transplant Surgery

Ohiohealth Corporation

500 Thomas Ln, 2e, 
Columbus, OH 
 (2.7 miles away)
614-566-9777
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Basem William is a Hematologist Oncology specialist and a Hospital Medicine provider in Columbus, Ohio. Dr. William is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. William is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Devarakonda's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 105 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile